๐๐จ๐ซ๐ฅ๐ ๐๐ฅ๐จ๐๐๐ฅ ๐ ๐๐ญ๐ญ๐ฒ ๐๐ข๐ฏ๐๐ซ ๐๐๐ฒ – ๐๐ฉ๐จ๐ญ๐ฅ๐ข๐ ๐ก๐ญ ๐จ๐ง ๐๐๐ฌ๐๐๐ซ๐๐ก ๐ข๐ง ๐๐๐๐
Today is ๐๐จ๐ซ๐ฅ๐ ๐๐๐๐ ๐๐๐ฒ. Itโs a time ๐ญ๐จ ๐ซ๐๐๐จ๐ ๐ง๐ข๐ณ๐ ๐ญ๐ก๐ ๐ซ๐๐ฌ๐๐๐ซ๐๐ก๐๐ซ๐ฌ, ๐๐ฅ๐ข๐ง๐ข๐๐ข๐๐ง๐ฌ, ๐ข๐ง๐ฌ๐ญ๐ข๐ญ๐ฎ๐ญ๐ข๐จ๐ง๐ฌ ๐๐ง๐ ๐๐จ๐ฆ๐ฉ๐๐ง๐ข๐๐ฌ working to better understand NASHย and improve outcomes for patients.
In an era of data overload, ๐ฆ๐๐ค๐ข๐ง๐ ๐ฌ๐๐ง๐ฌ๐ ๐จ๐ ๐ฆ๐ฎ๐ฅ๐ญ๐ข๐ฉ๐ฅ๐ ๐๐๐ญ๐๐ฌ๐๐ญ๐ฌ and ๐ฉ๐ซ๐จ๐ฆ๐จ๐ญ๐ข๐ง๐ ๐ญ๐ก๐ ๐ฏ๐ข๐ฌ๐ข๐๐ข๐ฅ๐ข๐ญ๐ฒ ๐จ๐ ๐ฆ๐๐๐ข๐๐๐ฅ ๐๐ฑ๐ฉ๐๐ซ๐ญ๐ฌ is key.
To mark the day, weโre sharing ๐ ๐ฌ๐ฅ๐ข๐๐๐ฌ๐ก๐จ๐ฐ ๐ก๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ข๐ง๐ ๐ค๐๐ฒ ๐๐๐ญ๐ ๐ข๐ง ๐๐๐๐ย ๐ซ๐๐ฌ๐๐๐ซ๐๐ก:
โข A ๐จ๐ญ๐ฐ๐ฃ๐ข๐ญ ๐ฎ๐ข๐ฑ ๐ฐ๐ง ๐ต๐ฐ๐ฑ ๐ณ๐ฆ๐ด๐ฆ๐ข๐ณ๐ค๐ฉ๐ฆ๐ณ๐ด in MASH
โข ๐๐ฏ๐ฏ๐ถ๐ข๐ญ ๐ต๐ณ๐ฆ๐ฏ๐ฅ๐ด in published research and clinical studies
โข ๐๐ข๐ช๐ฏ ๐ต๐ฐ๐ฑ๐ช๐ค๐ด in 2024/2025 publications
โข ๐๐ฐ๐ฑ 20 ๐ฆ๐น๐ฑ๐ฆ๐ณ๐ต๐ด based on impact and segmented on MASH
โข ๐๐ฐ๐ด๐ต ๐ข๐ค๐ต๐ช๐ท๐ฆ ๐ค๐ญ๐ช๐ฏ๐ช๐ค๐ข๐ญ ๐ด๐ช๐ต๐ฆ๐ด in Europe and US
This is a snapshot of where NASH research stands today โ and where it’s headed.
If you’re a ๐ฉ๐ก๐ฒ๐ฌ๐ข๐๐ข๐๐ง ๐จ๐ซ ๐ฌ๐๐ข๐๐ง๐ญ๐ข๐ฌ๐ญ ๐ฐ๐จ๐ซ๐ค๐ข๐ง๐ ๐ข๐ง NASH ๐จ๐ซ ๐ซ๐๐ฅ๐๐ญ๐๐ ๐๐ซ๐๐๐ฌ, join ScienceLeadR. Register or Log in with your ORCID, claim your profile,
and connect with peers focused on NASH research:https://lnkd.in/gJew3DBz
๐ ๐ข๐ง๐ ๐๐จ๐ฅ๐ฅ๐๐๐จ๐ซ๐๐ญ๐จ๐ซ๐ฌ, ๐ฌ๐ก๐๐ซ๐ ๐ฒ๐จ๐ฎ๐ซ ๐ฐ๐จ๐ซ๐ค, ๐๐ง๐ ๐ฌ๐ญ๐๐ฒ ๐ฎ๐ฉ๐๐๐ญ๐๐ with whatโs happening in the field.
Together, we can ๐๐ซ๐ข๐ฏ๐ ๐ข๐ง๐ง๐จ๐ฏ๐๐ญ๐ข๐จ๐ง ๐๐ง๐ ๐ข๐ฆ๐ฉ๐ซ๐จ๐ฏ๐ ๐จ๐ฎ๐ญ๐๐จ๐ฆ๐๐ฌ for patients with or at-risk of MASH.
NASH Insights
WorldNASHDay NASH MASH MedicalResearch ScientificExperts ClinicalTrials#KOL LifeSciences AI PatientsFirst